{"slideshow_credits": null, "snippet": "As an advisory panel prepared to consider whether to recommend federal approval of Pfizer\u2019s rheumatoid arthritis pill, F.D.A. documents raise safety questions.", "abstract": "Food and Drug Administration says an experimental pill being developed by Pfizer to treat rheumatoid arthritis raises 'serious safety concerns' and is linked to a higher risk for lymphoma and serious infections.", "section_name": "Health", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/05/08/health/fda-staff-raises-concerns-about-arthritis-drug.html", "lead_paragraph": "As an advisory panel prepared to consider whether to recommend federal approval of Pfizer\u2019s rheumatoid arthritis pill, F.D.A. documents raise safety questions.", "headline": {"seo": "F.D.A. Staff Raises Concerns About Arthritis Drug", "main": "F.D.A. Staff Raises Concerns About Arthritis Drug", "print_headline": "F.D.A. Staff Raises Concerns About Arthritis Drug"}, "_id": "53f6810d38f0d821a37b22bf", "word_count": "541", "multimedia": [], "pub_date": "2012-05-08T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Rheumatoid Arthritis", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Pfizer Inc", "name": "organizations", "is_major": "Y", "rank": "3"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}